Casgevy: What the First FDA-Approved CRISPR Therapy Actually Does

On December 8, 2023, the FDA approved Casgevy (exagamglogene autotemcel, or exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics. It was the first CRISPR-based therapy approved anywhere in the world. The UK's MHRA had approved it just days earlier, on November 16, 2023.

Casgevy treats two blood disorders: sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Both are genetic conditions affecting hemoglobin — the protein in red blood cells that carries oxygen.

The mechanism is indirect and elegant. Patients with SCD have a mutation in the beta-globin gene that causes their hemoglobin to polymerize under low oxygen conditions, distorting red blood cells into the characteristic sickle shape. These misshapen cells clog blood vessels, causing severe pain crises and organ damage. Direct correction of the beta-globin mutation is possible in principle, but technically complex.

Instead, Casgevy takes a different approach. It targets a gene called BCL11A.

Here's the logic: before birth, humans produce fetal hemoglobin (HbF), which doesn't have the same sickling problem as adult hemoglobin. After birth, BCL11A represses HbF production, switching the body to adult hemoglobin. Casgevy uses CRISPR to edit blood stem cells taken from the patient, disabling BCL11A's erythroid enhancer (a regulatory region, not the full gene). This reactivates HbF production. Enough fetal hemoglobin dilutes the adult hemoglobin, preventing the sickling phenomenon.

The process: patients undergo chemotherapy to clear space in the bone marrow, receive an infusion of their own edited stem cells, and then wait as those cells repopulate the bone marrow. It's grueling — typically requiring a hospital stay of several months.

Clinical trial results were striking. In the SCD trial, 97% of patients (29 out of 30) were free from severe pain crises for at least 12 consecutive months. In the TDT trial, 89% became transfusion-independent. These results were durable through the trial follow-up period.

The price: approximately $2.2 million per patient in the US. Access and equity are now the central issues.

Casgevy: What the First FDA-Approved CRISPR Therapy Actually Does

// COMMENTS

ON THIS PAGE